Hospira racks up higher Q1 sales; FDA OKs Novartis' Zykadia; Otsuka takes TB drug to EU;

@FiercePharma: Sources: Bayer offers animal health biz, cash for Merck's OTC unit. News | Follow @FiercePharma

@TracyStaton: Allergan to propose to Shire again, but does Irish beauty want to get engaged? Story | Follow @TracyStaton

@EricPFierce: The FDA is letting Baxter import saline from a plant in Spain to help ease the shortage in the US. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Advair slide, China woes drop-kick Glaxo profits in Q1. Article | Follow @CarlyHFierce

> Generic injectable drug specialist Hospira ($HSP) reported a 6.3% rise in Q1 sales of just over $1 billion compared to adjusted net sales in the same quarter a year ago. Release

> Novartis ($NVS) got FDA approval for Zykadia (ceritinib) for treating patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. Release

> Endo Health Solutions ($ENDP) has agreed to buy Mexico's Somar, a privately owned specialty pharma company, for an undisclosed amount. Report

> Franklin, TN-based Rare Disease Therapeutics has gotten FDA approval for Purixan (mercaptopurine) 20 mg/mL oral suspension, a liquid form of an established treatment for patients with Acute Lymphoblastic Leukemia (ALL). Release

> Japan's Otsuka Pharmaceutical has been granted EU approval for its delamanid tuberculosis drug, for treating pulmonary multidrug-resistant tuberculosis in adult patients. Story

> Italian pharmaceutical company Rottapharm Madaus, which is controlled by the Rovati family in Italy, has filed to be listed on the stock exchange in Milan. Report

Medical Device News

@FierceMedDev: The latest FierceDiagnostics is out, with scoops on Quest Diagnostics, Roche, VC funding and more. Read | Follow @FierceMedDev

@VarunSaxena2: Zogenix retaining rights to DosePro delivery technology in transaction with Endo. Story via FierceDrugDelivery | Follow @VarunSaxena2

@EmilyWFierce: ICYMI here's yesterday's issue of FierceBiotech Research (stories on MERS, Alzheimer's and HIV). Read | Follow @EmilyWFierce

@MichaelGFierce: Oramed's oral insulin PhIIa details show a compromised study, and shares continue to fall. More via FierceDrugDelivery | Follow @MichaelGFierce

> FDA deems faulty HeartWare tech potentially deadly. News

> Medtronic reveals positive data from new TAVR study for extreme-risk patients. More

> Teleflex teams up with Intuitive on next-gen da Vinci tech. Article

Biotech News

@FierceBiotech: GSK ups odds on heart drug hopeful with a changeup in endpoints. Story | Follow @FierceBiotech

@JohnCFierce: So after years of watching U.K. R&D get carved up like a cooked goose, lawmakers now want to probe the Pfizer deal? More | Follow @JohnCFierce

@DamianFierce: This list, via @JacobEPVantage, is like looking at an old yearbook. Qnexa was cute. I don't even recognize Sovaldi. Report | Follow @DamianFierce

@EmilyMFierce: ICYMI here's yesterday's issue of FierceBiotech Research: Report | Follow @EmilyMFierce

> Biopsy snafu torpedoes PhII prostate cancer data for Nymox. More

> Sanofi's MS team rebuilds its case for the FDA-rejected MS drug Lemtrada. Story

> Regeneron R&D chief's compensation shrinks, but still tops the chart. Article

Drug Delivery News

> Zogenix retaining rights to DosePro delivery technology in transaction with Endo. News

> Oramed's oral insulin PhIIa details show a compromised study, and shares continue to fall. Report

> Civitas announces positive results from Phase II inhaled levodopa trial. Story

> Cynapsus makes progress on sublingually delivered Parkinson's therapy. More

> Johns Hopkins team delivers cancer-killing DNA to mouse brains with nanovehicles. Article

> Imaging technique maps transdermal drug migration. Item

Diagnostics News

> Seattle firm attracts $47.25M for blood test that confirms benign lung nodules. News

> A certain protein marks tumors that will resist Astellas' prostate cancer drug Xtandi. Story

> Two new osteoarthritis biomarkers eyed for predictive Dx. More

> Quest to unveil new epilepsy tests in the wake of disappointing Q1 numbers. Article

> Roche-Evotec biomarker collaboration scores its first big milestone. Story

Pharma Marketing News

> Merck recruits ex-Law & Order star for new diabetes campaign. News

> With Big Pharma mergers in the works, whose SG&A costs look ripe for cutting? Report

> Sanofi bucks unit-sale trend with plan to unload $7B worth of older products. Item

> It's make-or-break time for GSK's new sales model as Anoro hits the U.S. market. Story

> GlaxoSmithKline dispatches sales and marketing team to clean up in China. More

> Simplify the DTC roll call of side effects? Yes, please, drugmakers tell FDA. Article

And Finally... The Andhra Pradesh High Court in India has put a temporary hold on Sun Pharmaceutical's $3.2 billion purchase of Ranbaxy Laboratories, while it considers a case brought by investors alleging insider trading ahead of the announcement. Story

Suggested Articles

Stephen Hahn, an oncologist who served as the chief medical officer for the MD Anderson Cancer Center, has secured Senate confirmation as FDA head.

As BMS searches for bright spots in its Opdivo-chemo combo fail from June, it’s zeroing in on squamous lung cancer patients who seemed to benefit.

The FDA's ad watchdog served its most serious violation to Alkermes Wednesday—and it took the unusual step of announcing that violation to the world.